Ephedrine Sulfate

Narcolepsy, Migraine, Catarrh + 13 more

Treatment

20 Active Studies for Ephedrine Sulfate

What is Ephedrine Sulfate

Ephedrine

The Generic name of this drug

Treatment Summary

Pseudoephedrine is a drug related to ephedrine and is extracted from plants that have been used in traditional Eastern medicine for centuries. Pseudoephedrine was first studied in the West in 1889 and its decongestant effect on dogs was discovered in 1927. It works by affecting the sympathetic nervous system, but not as strongly as ephedrine.

Rynatuss

is the brand name

image of different drug pills on a surface

Ephedrine Sulfate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Rynatuss

Ephedrine

1960

36

Effectiveness

How Ephedrine Sulfate Affects Patients

Pseudoephedrine helps to clear up congestion by narrowing blood vessels. It works quickly, but the effects may not last long unless it is taken as a special extended-release medication. Patients should be aware that taking pseudoephedrine can lead to stimulation of the central nervous system.

How Ephedrine Sulfate works in the body

Pseudoephedrine acts as a stimulant on your body, working on alpha and beta adrenergic receptors. This causes your blood vessels to narrow, making it useful for reducing congestion. It is also used to treat long-term erections. Pseudoephedrine also affects the way that hormones and neurotransmitters are transported throughout the body, increasing heart rate, blood pressure, and other bodily functions. It also blocks certain proteins from activating, which helps to reduce inflammation.

When to interrupt dosage

The suggested measure of Ephedrine Sulfate is contingent upon the diagnosed disorder, including Upper Respiratory Tract Infection, Airway secretion clearance therapy and Coughing. The quantity of dosage is contingent upon the method of delivery (e.g. Tablet, extended release or Oral) featured in the table beneath.

Condition

Dosage

Administration

Migraine

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Pharyngitis

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Narcolepsy

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Myasthenia Gravis

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Catarrh

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Acute Bronchitis

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Depression

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Rhinorrhea

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Asthma

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Coughing

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Arthralgia

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Nasal Congestion

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Upper Respiratory Disease

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Hypotension

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Fever

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Hypersensitivity

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, Tablet - Oral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Intravenous, Injection, solution - Intravenous, Liquid - Oral, Liquid - Nasal, Jelly, Jelly - Nasal, Injection - Intravenous, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Spray, Liquid - Infiltration; Subcutaneous, Infiltration, Infiltration; Subcutaneous, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous

Warnings

Ephedrine Sulfate has five contraindications and should not be used while experiencing any of the conditions outlined in the table below.

Ephedrine Sulfate Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Ephedrine Sulfate.

Common Ephedrine Sulfate Drug Interactions

Drug Name

Risk Level

Description

2,5-Dimethoxy-4-ethylamphetamine

Major

The therapeutic efficacy of 2,5-Dimethoxy-4-ethylamphetamine can be increased when used in combination with Ephedrine.

2,5-Dimethoxy-4-ethylthioamphetamine

Major

The therapeutic efficacy of 2,5-Dimethoxy-4-ethylthioamphetamine can be increased when used in combination with Ephedrine.

4-Bromo-2,5-dimethoxyamphetamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyamphetamine can be increased when used in combination with Ephedrine.

Acebutolol

Major

The therapeutic efficacy of Acebutolol can be increased when used in combination with Ephedrine.

Amphetamine/Dextroamphetamine

Major

The therapeutic efficacy of Amphetamine can be increased when used in combination with Ephedrine.

Ephedrine Sulfate Toxicity & Overdose Risk

The toxic dose of pseudoephedrine in rats is 2206mg/kg and 726mg/kg in mice. Symptoms of overdose may include dizziness, headache, nausea, vomiting, increased heart rate, chest pain, difficulty urinating, muscle weakness, anxiety, restlessness, insomnia, mental confusion, abnormal heart rhythms, loss of consciousness, seizures, and difficulty breathing. Treatment for an overdose should include supportive care and removal of the drug from the body.

Ephedrine Sulfate Novel Uses: Which Conditions Have a Clinical Trial Featuring Ephedrine Sulfate?

270 active trials are currently investigating the potential of Ephedrine Sulfate to mitigate Allergic Reactions, Migraines, and Eye Ailments.

Condition

Clinical Trials

Trial Phases

Pharyngitis

0 Actively Recruiting

Myasthenia Gravis

16 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1

Arthralgia

0 Actively Recruiting

Rhinorrhea

0 Actively Recruiting

Fever

2 Actively Recruiting

Not Applicable, Phase 4

Depression

300 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Hypotension

0 Actively Recruiting

Acute Bronchitis

8 Actively Recruiting

Phase 4, Not Applicable, Phase 3, Early Phase 1

Hypersensitivity

1 Actively Recruiting

Phase 4

Coughing

0 Actively Recruiting

Narcolepsy

2 Actively Recruiting

Not Applicable, Phase 1

Asthma

1 Actively Recruiting

Phase 4

Upper Respiratory Disease

0 Actively Recruiting

Nasal Congestion

0 Actively Recruiting

Catarrh

0 Actively Recruiting

Migraine

13 Actively Recruiting

Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4

Ephedrine Sulfate Reviews: What are patients saying about Ephedrine Sulfate?

4.7

Patient Review

12/12/2008

Ephedrine Sulfate for Bronchitis

4.3

Patient Review

4/9/2009

Ephedrine Sulfate for Bronchitis

I had never tried Bronkaid before, but I decided to give it a shot since I was struggling with my asthmatic bronchitis. I'm really glad I did- within half an hour, I could tell that it was working better than any other over the counter medication I've used for this problem.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ephedrine sulfate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does ephedrine do to a person?

"The ephedrine alkaloids are weak stimulants that can mildly increase heart rate and blood pressure, as well as relaxing bronchial tissue to ease shortness of breath."

Answered by AI

Is ephedrine sulfate a stimulant?

"Ephedrine is a central nervous system (CNS) stimulant that has been used to prevent low blood pressure during anesthesia, as well as for asthma, narcolepsy, and obesity. While it is not the preferred treatment, it is still used for these purposes."

Answered by AI

How do you take ephedrine sulfate?

"Ephedrine sulfate injection must be diluted with normal saline or 5% dextrose in water before administration as an intravenous bolus to achieve the desired concentration."

Answered by AI

What is ephedrine sulfate used for?

"This drug is indicated for the treatment of allergic disorders such as bronchial asthma. It has been used as a pressor agent for a long time, particularly during spinal anesthesia when hypotension is common."

Answered by AI

Clinical Trials for Ephedrine Sulfate

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Have you considered Ephedrine Sulfate clinical trials?

We made a collection of clinical trials featuring Ephedrine Sulfate, we think they might fit your search criteria.
Go to Trials
Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Arizona State University in Phoenix, United States.

App-based Breathing Program for Migraine

18+
All Sexes
Phoenix, AZ

Migraine is one of the most common neurological disorders, characterized by recurrent headaches, sensitivity to light and movement, nausea, and autonomic dysregulation. Although mind-body interventions like biofeedback have shown their efficacy, they remain underutilized due to barriers such as transportation, time constraints, lack of awareness, stigma, and cost. A targeted approach to enhancing HRV is HRV biofeedback (HRVB), a technique using visual or auditory feedback to help people regulate HRV through slow-paced breathing and positive emotional regulation to promote ANS balance and emotional resilience. Investigators will conduct a remotely delivered pilot RCT of an 8-week, 10 min/day, novel app-based HRVB intervention compared to a sham control intervention (matching intervention time and attention with no biofeedback component) in adult with chronic migraine. Investigators hypothesize data collected from the study will: a) support the feasibility and acceptability of the remotely delivered app-based HRVB intervention among adults with chronic migraine, and b) provide insights into refining the intervention by examining patterns of change in migraine and psychological outcomes from pre- to post-intervention.

Waitlist Available
Online Trial

Arizona State University

Have you considered Ephedrine Sulfate clinical trials?

We made a collection of clinical trials featuring Ephedrine Sulfate, we think they might fit your search criteria.
Go to Trials
Image of Lincoln Middle School in Cottage Grove, United States.

Behavioral Interventions for Depression in Students

Any Age
All Sexes
Cottage Grove, OR

The goal of this clinical trial is to learn if two behavioral interventions work to reduce office disciplinary referrals, improve attendance, and reduce depression and anxiety in 7th grade students. This project combines two evidence-based programs-the Inclusive Skill-building Learning Approach (ISLA) for school-wide discipline reform and the Family Check-Up Online (FCU-O) for family-centered support-in an adaptive design to examine the unique and additive effects of these interventions on these child behavior outcomes. The main questions it will answer are: 1. What is the relative efficacy of ISLA vs. School-as-Usual? 2. What is the optimal sequencing of these interventions? 3. Which overall sequence of intervention strategies was most effective? Researchers will compare 6 combinations of these interventions to see which combination and sequencing provides the best student outcomes. School personnel participating in the project will be trained to implement the two interventions at their school. They will answer surveys in the fall, winter, and spring of their year of participation. Parent and Youth participants will complete surveys at baseline and then again 6 months and 12 months later.

Waitlist Available
Has No Placebo

Lincoln Middle School (+12 Sites)

Beth Stormshak, PhD

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA

The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.

Waitlist Available
Has No Placebo

University of California San Diego

Have you considered Ephedrine Sulfate clinical trials?

We made a collection of clinical trials featuring Ephedrine Sulfate, we think they might fit your search criteria.
Go to Trials